Next 10 |
2024-06-25 09:00:00 ET Summary Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candid...
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients PR Newswire Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad lab...
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II PR Newswire Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval...
2024-06-14 07:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 07:17:07 ET More on Regenxbio Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy Regenxbio GAAP EPS of -$1.38 misses by $0.11, revenue of $15.62M misses by $7.9M Regenxbio Q1 2024 Earnings Preview Seeking Alpha’s...
REGENXBIO Announces Leadership Transition PR Newswire Curran Simpson , Chief Operating Officer, Appointed as President and CEO Co-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md. , Jun...
2024-06-10 23:55:53 ET Summary REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, a...
2024-06-07 12:30:06 ET H.C. Wainwright analyst issues BUY recommendation for RGNX on June 7, 2024 10:00AM ET. The previous analyst recommendation was Buy. RGNX was trading at $14.155 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire ROCKVILLE, Md. , June 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare C...
2024-06-02 15:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients PR Newswire Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad lab...
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II PR Newswire Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval...
2024-06-14 07:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...